Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AML Treatment Market Will Soar Beyond $930 Million by 2024

By GlobalData | December 9, 2015

The treatment market for Acute Myeloid Leukemia (AML) will rapidly expand in value from $342.7 million in 2014 to reach $932.6 million by 2024, representing a Compound Annual Growth Rate (CAGR) of 10.5%, says research and consulting firm GlobalData.

According to the company’s latest report*, this huge increase, which will occur across the seven major markets (7MM) of the US, Japan, the UK, Spain, Italy, France and Germany, will primarily be due to the launch of new therapies for AML patients with high unmet needs.

Sorcha Cassidy, Ph.D., GlobalData’s Analyst covering Oncology and Hematology, says the greatest unmet need in the market is improving the overall survival rate of elderly AML patients which, compared to that of younger favorable-risk patients, is substantially lower.

Cassidy comments: “Fulfilling this unmet need is a safe route to regulatory approval and commercial success. In this way, one of the major drivers of AML treatment sales across the 7MM will be the launch of premium-priced therapies for elderly AML patients, such as Ambit’s quizartinib.

“Other growth drivers will include an increasing branded drug treatment rate, a rising number of refractory/relapsed cases of AML across all age groups, and a growing desire to develop immunotherapies to treat AML patients.”

GlobalData’s report also states that by 2024, the branded AML market leader will be Vyxeos, with estimated total sales of $131 million in the US and five European countries.

Cassidy concludes: “GlobalData does not believe the efficacy of Vyxeos will be exceptional, but it will be an improvement on the current standard of care.

“However, the drug’s premium price, the sizeable population of elderly AML patients, and the absence of immediate competition will drive higher sales from Vyxeos than any other pipeline or marketed product.”

*OpportunityAnalyzer: Acute Myeloid Leukemia (AML) – Opportunity Analysis and Forecasts to 2024

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE